Baxter International BAX · NYSE
$22.98 -2.21% (-$0.52)
Summary
30 / 100 · Bulios Score
What speaks for it
- The price moves less than the market (beta 0.65).
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 10.0 years of operating profit.
- It cut its dividend by 50% last year.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 0.7% a year over 5 years. Over the last 3 years it grew by 3.8% a year. For the next fiscal year analysts expect revenue to grow by 3.3%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $723.0M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 108.7 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 0.17%
You receive $0.04 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 15
- Hold 20
- Sell 1
Today's price within the analysts' price targets
The average target of $23.6 is 2.7% above today's price. 42% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Medical Products And Therapies 49%
- Healthcare Systems and Technologies 28%
- Pharmaceuticals 23%
By region
- UNITED STATES 54%
- Western Europe, Canada, Japan, Australia and New Zealand 33%
- EMEA 12%
Medical Products And Therapies brings in 49% of revenue.
Segments in detail